BioMarin drug fails to show inattention, mood benefit in study

(Reuters) - BioMarin Pharmaceutical Inc's drug met the main goal of reducing a toxic buildup of an amino acid in the blood of patients with a genetic disorder, but did not show benefit in related inattention and mood complications.